CHARACTERIZATION OF SURFACTANT SUBTYPES OF BERACTANT AND A SYNTHETIC PEPTIDE-CONTAINING SURFACTANT KL4 FOLLOWING SURFACE-AREA CYCLING AND ADDITION OF FIBRINOGEN
E. Manalo et al., CHARACTERIZATION OF SURFACTANT SUBTYPES OF BERACTANT AND A SYNTHETIC PEPTIDE-CONTAINING SURFACTANT KL4 FOLLOWING SURFACE-AREA CYCLING AND ADDITION OF FIBRINOGEN, Lung, 175(4), 1997, pp. 225-233
Surfactant is not a homogeneous material and can be separated into sub
types. Subtype conversion is clinically important because it is though
t to occur naturally and because surface activity varies depending on
the subtype, Fibrinogen, a naturally occurring serum protein, is known
to affect this conversion. In this study we studied two surfactants,
beractant and KL4, to examine their subtype characteristics. Surface a
rea cycling, an in vitro method, was used in conjunction with sucrose
gradient ultracentrifugation to separate subtypes in both surfactants.
Activity, expressed as minimum surface tension of these subtypes, was
measured using a pulsating bubble surfactometer. The effect of fibrin
ogen on subtype conversion and subsequent change in activity was eluci
dated, Our results indicate that following surface area cycling, berac
tant and KL4 have different subtypes and different responses to fibrin
ogen. Cycling of beractant resulted in two bands, representing a heavy
and a light subtype. In the presence of fibrinogen, cycling resulted
in two separate heavy subtypes. Cycling of KL4 surfactant also yielded
light and heavy subtypes. However, in the presence of fibrinogen, cyc
ling of KL4 resulted in ultraheavy subtypes. These ultraheavy subtypes
retained minimum surface tension comparable to that of native KL4 sur
factant. We conclude that these two surfactant preparations have diffe
rent subtype conversions when subjected to surface area cycling and in
the presence of fibrinogen. These conversions result in different act
ivities toward lowering surface tension. we speculate that endogenous
fibrinogen will also affect these two surfactants differently in vivo
and thus affect their clinical effectiveness.